Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).
Researchers from the University of Southern Denmark have established a psilocybin microdosing regimen in rats to help advance microdosing research.
Dr Peter Sjöstedt-Hughes, Lecturer at Exeter University, has proposed incorporating metaphysical philosophy into psychedelic therapy to help improve therapeutic outcomes.
Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
